1-5 of 5
Thierry Horner, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson, MD, Manali Kamdar, MD, Brian J.P Huntly, Carlos Fernández De Larrea, MD PhD, Raul Cordoba, MD PhD, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Won-Seog Kim, MD PhD, Jin Seok Kim, MD PhD, Mark Dawson, MD PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, PhD, Aristeidis Chaidos, MD PhD, Alejandro Martín, MD, Thierry Horner, PhD, James Winnberg, MS, Lijoy K Mathew, PhD, Jeffrey Botbyl, MS, Natalie Karpinich, PhD, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS,MDPhD, Anastasios Karadimitris, FRCPath, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1682.
https://doi.org/10.1182/blood-2018-99-117089
Published: 2018
Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Mark Dawson, MD PhD, Eytan M. Stein, MD, Brian J.P Huntly, Anastasios Karadimitris, PhD, Manali Kamdar, Carlos Fernandez de Larrea, Michael J. Dickinson, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Naval Daver, MD, Aristeidis Chaidos, MD PhD, Martin S. Tallman, MD, Raquel Jiménez, MD, Thierry Horner, PhD, January Baron, MS, John Brennan, Geraldine Ferron-Brady, Yuehui Wu, PhD, Natalie Karpinich, Brandon Kremer, Arindam Dhar, MBBS,MDPhD, Gautam Borthakur, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1377.
https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377
Published: 2017
Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5223.
https://doi.org/10.1182/blood.V128.22.5223.5223
Published: 2016
Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD
Journal: Blood
Blood (2016) 128 (22): 4203.
https://doi.org/10.1182/blood.V128.22.4203.4203
Published: 2016
Journal Articles

Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.

Mark S. Kaminski, MD, Melissa Tuck, MS, Judith Estes, BSN, MSN, Arne Kolstad, MD, PhD, Charles Warren Ross, MD, Denise Regan, BS, Thierry Horner, PhD, Vanessa C. Williams, MS, Tina Vleisides, DC, Richard L. Wahl, MD
Journal: Blood
Blood (2009) 114 (22): 3759.
https://doi.org/10.1182/blood.V114.22.3759.3759
Published: 2009